This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Abaloparatide
Synthetic PTHrP 1-34 analog approved 2017 (FDA) for severe postmenopausal osteoporosis.
Aliases (3)
Overview
What is Abaloparatide?
Abaloparatide (brand name Tymlos) is a synthetic 34-amino-acid analog of parathyroid hormone-related protein (PTHrP). It is FDA-approved for the treatment of postmenopausal osteoporosis at high risk of fracture. Administered once daily by subcutaneous injection.
Key Benefits
Increases bone mineral density at the spine and hip, reduces vertebral and non-vertebral fracture risk, and acts as a true anabolic bone agent (builds new bone, vs. antiresorptive drugs that only slow loss).
Mechanism of Action
Selective agonist of the PTH1 receptor RG conformation, preferentially stimulating osteoblast-mediated bone formation with minimal sustained osteoclast activation. Net result is anabolic bone remodeling with less hypercalcemia than teriparatide.
Pharmacokinetics
Research Indications
R0
high-affinity, prolonged signaling (favors sustained activation → catabolic to bone, hypercalcemic)
RG
transient signaling, G-protein coupled (favors brief activation → preferentially anabolic to bone)
Peptide Interactions
Locks in gains
Required co-administration — anabolic peptide demands calcium and D substrate
Theoretical support for calcium-direction-to-bone vs vascular calcification
Same receptor — additive osteosarcoma signal concern
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety
- Common (>10%): Injection-site reaction (erythema, mild pain), nausea, headache, dizziness
- Less common (1-10%): Orthostatic hypotension within 4 hours of dose, palpitations, hypercalcemia (3-4% — meaningfully lower than teriparatide's ~6%), abdominal pain, vertigo
- Rare-serious (<1%): Osteosarcoma (rodent signal at supratherapeutic chronic doses; black-box warning carried over from teriparatide; no confirmed human cases linked to abaloparatide)
- Specific watch periods: First few doses — orthostatic hypotension is most common in first hour. Patients are typically advised to sit down for several minutes after injection. Calcium monitoring at 1-3 months.
References
Miller et al. 2016 — ACTIVE trial: abaloparatide vs placebo vs teriparatide (JAMA)
Czerwinski et al. 2022 — ATOM trial: abaloparatide in men with osteoporosis (J Bone Miner Res)
Hattersley et al. 2016 — Abaloparatide RG-conformation receptor selectivity (Endocrinology)
Reginster et al. 2019 — Position paper on anabolic agents in osteoporosis
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.